Calcico is a biotechnology company focused on the development of novel CRAC channel inhibitors.
The company aims to develop selective small molecules to treat a range of inflammatory and autoimmune conditions where there is clear evidence linking CRAC to human disease.
Calcico was spun-out from Oxford University in April 2012 and funded by Advent Life Sciences and Touchstone Innovations. The company has developed proprietary ‘know-how’ comprising novel systems for selective CRAC channel screening and molecule characterisation. This puts the company in a unique position to achieve the goal of potent and selective CRAC channel inhibition, which has so far eluded pharmaceutical companies.